[go: up one dir, main page]

BRPI0411854A - veìculos protéicos para vacinas - Google Patents

veìculos protéicos para vacinas

Info

Publication number
BRPI0411854A
BRPI0411854A BRPI0411854-5A BRPI0411854A BRPI0411854A BR PI0411854 A BRPI0411854 A BR PI0411854A BR PI0411854 A BRPI0411854 A BR PI0411854A BR PI0411854 A BRPI0411854 A BR PI0411854A
Authority
BR
Brazil
Prior art keywords
vaccines
protein vehicles
based vaccines
vehicles
protein
Prior art date
Application number
BRPI0411854-5A
Other languages
English (en)
Inventor
Francis J Michon
John Kim
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of BRPI0411854A publication Critical patent/BRPI0411854A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"VEìCULOS PROTéICOS PARA VACINAS". A presente invenção refere-se, entre outras coisas, a veículos protéicos aperfeiçoados para vacinas à base de antígenos, inclusive vacinas à base de polissacarídeos. Um aspecto da invenção emprega vantajosamente o Fragmento C da toxina tetânica.
BRPI0411854-5A 2003-06-23 2004-06-23 veìculos protéicos para vacinas BRPI0411854A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48040903P 2003-06-23 2003-06-23
PCT/US2004/020026 WO2005000346A1 (en) 2003-06-23 2004-06-23 Carrier proteins for vaccines

Publications (1)

Publication Number Publication Date
BRPI0411854A true BRPI0411854A (pt) 2006-08-29

Family

ID=33551917

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411854-5A BRPI0411854A (pt) 2003-06-23 2004-06-23 veìculos protéicos para vacinas

Country Status (12)

Country Link
US (1) US7972608B2 (pt)
EP (1) EP1638601B1 (pt)
JP (1) JP4764820B2 (pt)
KR (2) KR101206544B1 (pt)
AT (1) ATE414535T1 (pt)
AU (1) AU2004251726B2 (pt)
BR (1) BRPI0411854A (pt)
CA (1) CA2530363C (pt)
DE (1) DE602004017864D1 (pt)
ES (1) ES2317043T3 (pt)
MX (1) MXPA05014016A (pt)
WO (1) WO2005000346A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003295520B8 (en) 2002-11-12 2011-05-19 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for Staphylococcal infections
GB0522303D0 (en) * 2005-11-01 2005-12-07 Chiron Srl Culture method
PE20120262A1 (es) * 2006-03-30 2012-03-30 Glaxosmithkline Biolog Sa Procedimiento para la preparacion de inmunoconjugados que comprenden polisacarido u oligosacarido capsular de s. aureus junto con la proteina portadora
BRPI0710210A2 (pt) * 2006-03-30 2011-05-24 Glaxomithkline Biolog S A composição imunogênica, vacina, métodos para preparar a vacina, e para prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, e, processo para conjugar oligassacarìdeo ou polissacarìdeo capsular
KR20150041178A (ko) 2008-07-21 2015-04-15 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
ES2812523T3 (es) 2009-09-30 2021-03-17 Glaxosmithkline Biologicals Sa Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
RS56000B1 (sr) * 2009-10-30 2017-09-29 Glaxosmithkline Biologicals Sa Prečišćavanje stafilokokus aureus tip 5 i tip 8 kapsuliranih saharida
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
BR112012024898A2 (pt) 2010-03-30 2015-10-06 Pfenex Inc expressão de nível elevado de proteínas recombinantes de toxinas
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
AU2012335208B2 (en) 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
CN102809655B (zh) * 2012-08-26 2014-05-21 玉溪沃森生物技术有限公司 一种脑膜炎球菌多糖结合疫苗成品各群多糖含量的测定方法
AU2013326503B2 (en) 2012-10-03 2018-04-19 Glaxosmithkline Biologicals Sa Immunogenic composition
EP2724730A1 (en) 2012-10-29 2014-04-30 Institut Pasteur Glycoconjugates and their use as potential vaccines against infection by Shigella Flexneri
WO2014147287A1 (en) 2013-03-21 2014-09-25 Jukka Seppälä Nanocrystalline cellulose (ncc) as an antiviral compound
US20170151316A1 (en) 2014-07-02 2017-06-01 Spherium Biomed, S.L. Methods of increasing muscle mass using non-toxic tetanus toxin c fragment (ttc)
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3292146A1 (en) 2015-05-04 2018-03-14 Pfizer Inc Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
BE1024634B1 (fr) 2016-04-05 2018-05-14 Gsk Vaccines S.R.L. Compositions immunogenes
SI3506935T1 (sl) 2016-09-02 2024-06-28 Sanofi Pasteur, Inc. Cepivo proti neisseriji meningitidis
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3638301A1 (en) 2017-06-16 2020-04-22 GlaxoSmithKline Biologicals S.A. Method of treatment
WO2021099982A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
KR20230123464A (ko) * 2020-10-20 2023-08-23 상하이 레이노박스 바이올로직스 컴퍼니 리미티드 프로테오글리칸 접합체 및 이의 응용
US20240024489A1 (en) 2020-11-20 2024-01-25 Institut Pasteur Protected disaccharides, their process of preparation and their use in the synthesis of zwitterionic oligosaccharides, and conjugates thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4062905A (en) * 1976-08-02 1977-12-13 Mobil Oil Corporation Manufacture of light olefins
US4079095A (en) * 1976-11-04 1978-03-14 Mobil Oil Corporation Manufacture of light olefins
US4310440A (en) * 1980-07-07 1982-01-12 Union Carbide Corporation Crystalline metallophosphate compositions
US4440871A (en) * 1982-07-26 1984-04-03 Union Carbide Corporation Crystalline silicoaluminophosphates
US4677242A (en) * 1982-10-04 1987-06-30 Union Carbide Corporation Production of light olefins
US4499327A (en) * 1982-10-04 1985-02-12 Union Carbide Corporation Production of light olefins
US4677243A (en) * 1982-10-04 1987-06-30 Union Carbide Corporation Production of light olefins from aliphatic hetero compounds
US4673559A (en) * 1983-12-19 1987-06-16 Mobil Oil Corporation Silicoaluminophosphate crystallization using hydrolysis
US5047141A (en) * 1984-07-16 1991-09-10 Mobil Oil Corporation Larger pore molecular sieves of controlled activity
US4873390A (en) * 1987-07-07 1989-10-10 Uop Chemical conversion process
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5141729A (en) * 1988-04-08 1992-08-25 Mobil Oil Corporation Synthesis of crystalline metalloaluminophosphate composition
GB8914122D0 (en) * 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5095163A (en) * 1991-02-28 1992-03-10 Uop Methanol conversion process using SAPO catalysts
EP0568913A3 (en) * 1992-05-03 1995-03-22 Dalian Chemical Physics Inst Process for the conversion of methanol into light olefins and catalyst used therefor.
NZ248766A (en) * 1992-09-24 1996-11-26 Ca Nat Research Council Capsular polysaccharide-protein conjugate vaccine against group b streptococcus type ii or v
EP0712442B1 (en) * 1993-07-30 2002-03-27 Medeva Holdings B.V. Vaccine compositions
US6284884B1 (en) * 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
JP5132851B2 (ja) * 1997-08-05 2013-01-30 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） 新しい免疫防御性インフルエンザ抗原及びそのワクチン接種への使用
GB9720033D0 (en) * 1997-09-19 1997-11-19 Medeva Plc Hepatitis B virus polypeptides
US6482998B1 (en) * 1998-04-29 2002-11-19 Exxonmobil Chemical Patents, Inc. Process for converting oxygenates to olefins with direct product quenching for heat recovery
US6166282A (en) * 1999-08-20 2000-12-26 Uop Llc Fast-fluidized bed reactor for MTO process
GB0009470D0 (en) * 2000-04-17 2000-06-07 Univ Southampton Materials and methods relating to immune responses to fusion proteins
AU2003257003A1 (en) * 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines

Also Published As

Publication number Publication date
KR20060041184A (ko) 2006-05-11
JP4764820B2 (ja) 2011-09-07
EP1638601B1 (en) 2008-11-19
CA2530363A1 (en) 2005-01-06
KR20120101580A (ko) 2012-09-13
US7972608B2 (en) 2011-07-05
MXPA05014016A (es) 2006-03-17
CA2530363C (en) 2013-05-07
KR101206544B1 (ko) 2012-11-30
EP1638601A1 (en) 2006-03-29
WO2005000346A1 (en) 2005-01-06
AU2004251726A1 (en) 2005-01-06
KR101318320B1 (ko) 2013-10-15
DE602004017864D1 (de) 2009-01-02
JP2007524621A (ja) 2007-08-30
ATE414535T1 (de) 2008-12-15
AU2004251726B2 (en) 2010-01-28
ES2317043T3 (es) 2009-04-16
US20070014812A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
BRPI0411854A (pt) veìculos protéicos para vacinas
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1119106T1 (el) Αντισωματα εναντι masp-2
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
CY1119416T1 (el) Αντισωματα εναντι των τοξινων toy clostridium difficile (κλωστηριδιο το δυσκολο) και χρησεις εξ' αυτων
TW200510459A (en) RG1 antibodies and uses thereof
TNSN08255A1 (en) Anti-mn antibodies and methods of using same
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
CY1116913T1 (el) Τροποποιημενα κλασματα fab αντισωματων
DE602006013029D1 (de) Anti-egfr-antikörper
CY1114851T1 (el) Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων
CY1109683T1 (el) Αντιγονα του streptococcus pyogenes
WO2006113546A3 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
DK2316852T3 (da) Stabiliserede enkeltdomæne-antistoffer
CY1114855T1 (el) Αντισωματα και μορια που προερχονται απο αυτα που δεσμευονται στις πρωτεϊνες toy steap-1
CY1114658T1 (el) Πρωτεϊνες δεσμευσης αντιγονου του αυξητικου παραγοντα τυπου επιδερμικου αυξητικου παραγοντα προσδεσης στην ηπαρινη
ATE554107T1 (de) Als therapeutika geeignete monovalente antikörperfragmente
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
WO2004063963A3 (en) Novel proteins with altered immunogenicity
NO20054836L (no) Nogo-reseptorbindingsprotein
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
DE60025704D1 (de) Das goodpasture-antigen bindende protein
WO2005099361A3 (en) MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: BAXTER INTERNATIONAL INC. (US) , BAXTER HEALTHCARE

Free format text: ENDERECO DO 2O DEPOSITANTE ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110115944/RJ DE 11/11/2011.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.